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ABSTRACT  53 
 54 
To characterise the genetics of splenic marginal zone lymphoma (SMZL), we performed whole 55 
exome sequencing of 16 cases and identified novel recurrent inactivating mutations in KLF2, a gene 56 
whose deficiency was previously shown to cause splenic marginal zone hyperplasia in mice.  KLF2 57 
mutation was found in 40 (42%) of 96 SMZLs, but rarely in other B-cell lymphomas.  The majority of 58 
KLF2 mutations were frameshift indels or nonsense changes, with missense mutations clustered in 59 
the C-terminal zinc finger domains.  Functional assays showed that these mutations inactivated the 60 
ability of KLF2 to suppress NF-B activation by TLR, BCR, BAFFR and TNFR signalling.  Further 61 
extensive investigations revealed common and distinct genetic changes between SMZL with and 62 
without KLF2 mutation.  IGHV1-2 rearrangement and 7q deletion were primarily seen in SMZL with 63 
KLF2 mutation, while MYD88 and TP53 mutations were nearly exclusively found in those without 64 
KLF2 mutation.  NOTCH2, TRAF3, TNFAIP3 and CARD11 mutations were observed in SMZL both with 65 
and without KLF2 mutation.  Taken together, KLF2 mutation is the most common genetic change in 66 
SMZL and identifies a subset with a distinct genotype characterised by multi-genetic changes.   These 67 
different genetic changes may deregulate various signalling pathways and generate cooperative 68 
oncogenic properties, thereby contributing to lymphomagenesis. 69 
 70 
  71 
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INTRODUCTION   73 
 74 
Splenic marginal zone lymphoma (SMZL), a low grade B-cell lymphoma, is difficult to diagnose 75 
accurately due to a lack of specific histological, immunophenotypic and genetic markers.1  Patients 76 
with SMZL present with a highly variable clinical course with the majority showing a median survival 77 
of 10 years, ~25% of cases die of the disease within 5 years and a further ~5% of cases display high-78 
grade transformation.2,3  Despite the advances in treatment of other lymphomas, the survival of 79 
patients with SMZL has not been improved over the last decade.4  These dilemmas in diagnosis and 80 
clinical management are largely due to poor understanding of its genetics and molecular mechanism.              81 
 82 
There is mounting evidence suggesting a role for antigenic stimulation in the pathogenesis of SMZL.  83 
Approximately 20% of patients with SMZL present with autoimmune phenomena.  A small 84 
proportion of cases are associated with HCV infection and can be effectively treated by antiviral 85 
therapy.5  Importantly, >30% of SMZL has biased usage of IG heavy chain variable gene, IGHV1-2.6,7  86 
Most of the IGHV1-2 rearrangements are characterised by minimal somatic mutations and longer 87 
complementarity determining region-3 (CDR3) sequence with common motifs, suggesting a possible 88 
selection by superantigens.7   Together, these findings indicate a critical role of active BCR signalling 89 
in the pathogenesis of SMZL.   90 
 91 
SMZL lacks recurrent chromosome translocations.  Approximately 30% of SMZLs show hemizygous 92 
7q deletion, which is also seen frequently in splenic B-cell lymphoma/leukaemia unclassifiable 93 
(SBCLU), but rarely in other lymphoma subtypes.8-10  The gene(s) targeted by the 7q deletion remain 94 
obscure despite the combined investigation of genomic and transcriptomic profiles and mutation 95 
analysis of a number of candidate genes.11,12 96 
 97 
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Recent studies  by whole exome sequencing (WES) identified a plethora of somatic mutations in 98 
SMZL.13-16  These studies together with candidate gene sequencing showed a diverse spectrum of 99 
mutations in the NOTCH, NF-κB, BCR and TLR pathways, and in histone modifiers and transcriptional 100 
regulators.13-18  Most of these mutations were found in <10% of cases, with only NOTCH2 mutations 101 
occurring more frequently, but variably among different studies (6.5-25%).13-16  Importantly, a 102 
significant proportion of SMZL lack any of these candidate pathogenic mutations.  As the number of 103 
cases investigated by WES in each of the above studies was small (6-15 cases),13-16 the mutation 104 
landscape in SMZL is likely not yet fully characterised.   In this study, we identified further novel 105 
recurrent mutations in SMZL by WES and showed that KLF2 (Kruppel-like factor 2) was inactivated by 106 
mutations in 42% of SMZL.  Mechanistically, KLF2 mutations abrogated KLF2-mediated suppression 107 
of NF-B activation by TLR, BCR, BAFFR and TNFR signaling.  KLF2 mutation is significantly associated 108 
with 7q deletion, IGHV1-2 usage, NOTCH2, TNFAIP3 and TRAF3 mutation, and may potentially 109 
cooperate with these genetic changes in oncogenesis.  110 
 111 
MATERIALS AND METHODS 112 
 113 
Patients samples:  Tumour DNA was extracted from 105 cases of SMZL (77 from fresh frozen [FF] 114 
lymphoma tissues, 3 from leukemic peripheral blood samples, 25 from formalin-fixed paraffin-115 
embedded [FFPE] lymphoma tissue), SBCLU (n=3 ), chronic lymphocytic leukaemia (CLL, n=39, all 116 
from bone marrow aspirate), hairy cell leukaemia (HCL, n=30, all from bone marrow aspirate), 117 
extranodal marginal zone lymphoma of mucosa-associated lymphoma tissue (MALT lymphoma, n=47, 118 
all from FFPE diagnostic tissue biopsies), mantle cell lymphoma (MCL, 7 from FF and 4 from FFPE 119 
diagnostic tissue biopsies), follicular lymphoma (FL, 5 from FF and 6 from FFPE diagnostic tissue 120 
biopsies), and diffuse large B-cell lymphoma (DLBCL, n=28, all FFPE diagnostic tissue biopsies).  The 121 
lymphoma diagnosis was made according to the 2008 WHO classification of tumours of 122 
haematopoietic and lymphoid tissues.  Where indicated, germline DNA was prepared from non-123 
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neoplastic cells of tissues.  The DNA quality was assessed by PCR of variably sized genomic 124 
fragments,19 and samples with successful amplifications of >300bp were used for genetic analyses.   125 
Partial data on 7q deletion and IGHV usage in SMZL were available from previous studies,10-12 with all 126 
other genetic data collected in this study.  Local ethical guidelines were followed for the use of 127 
archival tissues for research with the approval of the ethics committees of the involved institutions. 128 
 129 
Exome sequencing and somatic variant calling:   These were carried out by the Wellcome Trust 130 
Sanger Institute.  High molecular weight (HMW) tumour DNA samples from 16 cases of SMZL and 131 
matched  germline DNA samples from 3 of these cases (non-neoplastic FFPE tissues in 1, buccal swap 132 
or non-involved peripheral blood sample in 2) were used to generate genomic libraries with the 133 
Illumina Paired End Sample Prep Kit (Table S1).  Enrichment was performed using the Agilent 134 
SureSelect Human All Exon 50Mb kit.20-22   Each exome was sequenced using a 75bp paired-end 135 
protocol on an Illumina HiSeq platform.  Sequencing reads were aligned to the hg19 reference 136 
genome using the BWA algorithm on default settings.  137 
 138 
Novel variants were called by comparison of tumour and germline sequence reads.  CaVEMan 139 
(Cancer Variants through Expectation Maximisation) was used to call single nucleotide substitution,21 140 
while Pindel was used to call insertions and deletions.23  Post processing filters were applied to 141 
increase the specificity of the output, remove variants reported in poor quality sequences and 142 
remove known SNPs in databases and unmatched normals from this study and the 10,000 genomes 143 
project.  144 
 145 
Somatic variant validation by PCR and Sanger sequencing:   Where indicated, novel variants 146 
identified by WES and their potential somatic origin were first confirmed by PCR and Sanger 147 
sequencing.  Depending on the nature of gene sequences, different approaches were employed for 148 
mutation screening.  Mutations in KLF2 were screened by PCR and Sanger sequencing as the gene 149 
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has a high GC content (Table S2).    In each case, sequence change was confirmed by at least two 150 
independent PCR and sequencing experiments.  The somatic mutation was ascertained by excluding 151 
germline changes through SNP database search and analysis of germline DNA samples where 152 
possible.     153 
 154 
Somatic variant validation by Fluidigm Access Array PCR  and Illumina MiSeq sequencing:   155 
Mutations in NOTCH2, TNFAIP3, TRAF3, MYD88, IKBKB, CARD11, BCL10, CD79A, CD79B and TP53 156 
were screened by massive parallel Fluidigm Access Array PCR and Illumina MiSeq sequencing using 157 
our established protocol from a parallel investigation (manuscript in preparation).  The in house 158 
variant calling algorithm was developed and optimised against a large number of various known 159 
somatic mutations by Sanger sequencing.  Please refer to Supplementary Methods for experimental 160 
details and variant calling algorithms (Table S3).  Each sample was investigated in duplicate to 161 
eliminate any potential false positives.  Any novel variants seen in both replicates of the same 162 
sample were further ascertained by an independent Fluidigm PCR and MiSeq sequencing or Sanger 163 
sequencing.  Where indicated, their somatic nature was confirmed by PCR and Sanger sequencing of 164 
the paired non-tumour DNA sample, or by search of COSMIC somatic mutation database.     165 
NF-B reporter assay:  The full-length coding sequence and various truncated forms of KLF2 were 166 
amplified from pCMV6-AC-GFP (OriGene, USA) by PCR and cloned into the pIRES-puro2-HA vector at 167 
the EcoRI and BamHI sites.  The KLF2 mutant containing a single point mutation was generated from 168 
the wild type using the QuickChange Site-directed mutagenesis kit (Stratagene, USA).  PCR and 169 
sequencing were performed to verify the KLF2 sequence and reading frame.  The effect of KLF2 and 170 
its mutants on suppression of NF-B activation by various stimuli (TNFα, BAFF, mutant MYD88  or 171 
mutant CARD11) was investigated where appropriate in both HEK293T and OCI-LY19 human B-cell 172 
lymphoma cell lines using a Dual-Luciferase reporter assay (Promega, UK).24,25  Please refer to  173 
Supplementary Methods for experimental details.  174 
 175 
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 176 
Analysis of rearranged IGH genes by PCR and Sanger sequencing:   The rearranged IGH genes were 177 
amplified using BIOMED-2 FR1 and consensus JH primer sets.26  The PCR product was purified and 178 
sequenced as previously described.10  The VH sequence was identified using the IMGT/V-QUEST 179 
database (http://www.imgt.org).  Cases harbouring < 97% homology were considered significantly 180 
mutated, while those with 97-99.9% identity were regarded minimally mutated.7 181 
 182 
Statistical analyses:  The student's t-test was performed using GraphPad Prism version 5.00 183 
software (GraphPad Software, San Diego, USA).  The correlation among categorical variables was 184 
evaluated by Fisher's exact probability test.  Overall survival (OS) was measured from the date of 185 
diagnosis to death from any cause.  Probabilities of OS were calculated by the Kaplan–Meier method, 186 
and the comparison between subgroups was performed via the log-rank test.  Kaplan-Meier analysis, 187 
log-rank test and Fisher’s exact test were carried out using SPSS, version 13. 188 
 189 
RESULTS  190 
 191 
Identification of KLF2 mutation by WES 192 
 193 
WES was successful for all 16 tumour and 3 matched germline DNA samples (Table S4).  Based on 194 
the 3 cases with matched germline DNA, a total of 174 variants in 163 genes (average 58/case; range 195 
45-82/case) were seen, with variants in 135 genes being novel, not reported previously in SMZL 196 
(Table S5). The number of variants in the remaining cases was much higher due to a lack of WES data 197 
from matched germline DNA, thus preventing the filter of all SNPs.    Nonetheless, a total of 223 198 
variants  were observed in 159 genes known to be mutated in SMZL by previous studies, including 199 
those described in the NOTCH2 signalling pathway (NOTCH2, NOTCH4, SPEN), NF-B pathway 200 
(TNFAIP3, TRAF3, BIRC3), BCR pathway (CARD11) and TLR pathway (MYD88) (Figure S1).13-16  201 
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Comparative analyses of the exome sequencing data from the 4 published WES studies also revealed 202 
little overlap among the variants identified in these studies (Figure S2).13-16  Together, these findings 203 
suggest the presence of a remarkable heterogeneity or incomplete discovery of the somatic 204 
mutation profile in SMZL, or both.      205 
 206 
Among the variants not reported previously, there were several recurrent changes not seen in the 207 
matched control DNA.  Based on the frequency, possible functional impact and a comprehensive 208 
literature search, we identified KLF2 mutation as a potentially significant genetic abnormality in 209 
SMZL (Figure S1).   Among the 16 SMZLs investigated by WES in this study, KLF2 mutation was seen 210 
in 5 cases, all being deleterious changes (frameshift insertion/deletion in 2, nonsense mutation in 2, 211 
and substitution change at an essential splice site in 1 case).  Further PCR and Sanger sequencing 212 
confirmed these mutations, and their somatic origin in all 5 cases.  In support of the pathogenic 213 
importance of these mutations in SMZL, Klf2 deficient mice were previously shown to have a marked 214 
increase in marginal zone B-cells and splenic marginal zone hyperplasia.27-29   215 
 216 
KLF2 is frequently targeted by mutation in SMZL. 217 
 218 
Next, we investigated KLF2 mutation in 96 cases of SMZL including 13 of the 16 cases investigated by 219 
WES, and 7 other B-cell lymphoma entities to determine its frequencies and mutation spectrum.  As 220 
the KLF2 gene has a high GC content that may have accounted for the failure of detection of its  221 
mutation by previous exome sequencing studies,13-16   PCR and Sanger sequencing were used for 222 
mutation screening.  A total of 47 KLF2 mutations were seen in 40 (42%) of the 96 cases of SMZL 223 
with double mutations in 7 cases, and their somatic nature was confirmed in each of the 8 cases 224 
(including 3 indels and 7 substitutions), for which non-tumour DNA was available (Figure 1A, Figure 225 
S3, Table S6).  Of note, Sanger sequencing identified 4 additional mutations in 3 cases missed by WES, 226 
which included 1 frameshift deletion, 1 in-frame deletion and 2 missense substitutions.   In contrast, 227 
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KLF2 mutation was not or rarely seen in SBCLU (0/3), CLL (0/39), HCL (3/30), FL (1/11), MCL (1/11), 228 
MALT lymphoma (2/47) and DLBCL (0/28) (Figure 1B).        229 
 230 
Among the 47 KLF2 mutations identified in SMZL, 27 were frameshift insertions / deletions, 231 
nonsense mutations, or substitutions affecting the essential splice site, thus resulting in a potentially 232 
truncated protein product (Figure 1A).   Importantly, a high proportion of these deleterious 233 
mutations were localised toward the N-terminal activation domain (AD) and middle inhibitory 234 
domain (ID).  The remaining 20 mutations seen in SMZL were 19 missense substitutions and 1 in-235 
frame deletion, with 12 clustered in the C-terminal zinc finger (ZF) 1, mainly at conserved amino acid 236 
residues (Figure 1A).  Fourteen missense mutations  were predicted to be damaging by the 237 
PolyPhen-2 program,30 and a further 2 missense mutations abolished the stop codon with potential 238 
extension of a further 62 amino acids.   Among the 7 KLF2 mutations found in other lymphoma 239 
entities, 2 were frameshift deletions in the ID and ZF3 domains respectively, and 5 were missense 240 
mutations with only 1 in the C-terminal ZF1 domain (Figure 1A).      241 
 242 
Functional characterisation of KLF2 mutations   243 
 244 
The nature and distribution of the KLF2 mutations suggest that these genetic changes are likely to 245 
inactivate KLF2 function.  We thus generated a series of KLF2 expression constructs, representing 246 
various C-terminal truncated products that were lacking 1 or more ZF domains, and recurrent 247 
missense or in-frame deletion mutants that affected conserved amino acid residues in the ZF1 248 
domain, and tested their impact on KLF2 function using in vitro reporter assays in both HEK293T and 249 
OCI-LY19 B-lymphoma cells.    Previous studies have shown that KLF2 inhibits the transcriptional 250 
activity of NF-κB.31  We therefore tested the ability of various KLF2 mutants to suppress NF-κB 251 
activation by TNFα, MYD88(S219C), CARD11(F130V) and BAFF, which were used to activate TNFR, 252 
TLR, canonical and non-canonical NF-κB signalling pathways respectively.  253 
    Clipson et al 
11 
 
 254 
 255 
As expected, wild type KLF2 was highly potent in the suppression of NF-κB activation by different 256 
signalling pathways including stimulation by TNFα, MYD88(S219C), CARD11(F130V) and BAFF  257 
(Figure 2B).   With the exception of KLF2-A291V mutant, all other 5 mutants including KLF2-C274Y 258 
and KLF2-TY mutants showed a total or major loss in NF-κB suppression, although to varying 259 
extents depending on stimuli used to activate NF-κB.  Interestingly, both cases with KLF2-A291V had 260 
a second mutation, one with P70S in the activation domain, the other with C274S, at which a C274Y 261 
change was shown to impair KLF2 function as described above (Table S6). 262 
 263 
KLF2 mutation identifies a subset of SMZL with distinct genotypes    264 
 265 
To further characterise the genetics of SMZL and understand their potential cooperation in 266 
lymphomagenesis, we comprehensively investigated somatic mutations in NOTCH2, TNFAIP3, TRAF3, 267 
MYD88, CD79A, CD79B, CARD11, BCL10, IKBKB and TP53 (Figure 3, Table S6), 7q deletion and IGHV 268 
usage in the entire cohort of SMZL and correlated their changes with KLF2 mutation using the 269 
Fisher's exact probability test.  The analyses revealed several significant associations.  270 
 271 
First, KLF2 mutation identified a subset of SMZL with distinct genetic changes.   The mutation was 272 
significantly associated with both 7q deletion (P=7.3310-7) and IGHV1-2 usage (P=1.0210-7), seen 273 
in 77% cases with 7q deletion and 83% of those with IGHV1-2 (Figure 4).  As with previous studies,6,7 274 
the rearranged IGHV1-2 was characterised by minimal somatic mutations (Figure 4A).     275 
 276 
Second, mutations in the NOTCH2, TRAF3, TNFAIP3 and CARD11 genes were found in SMZL both 277 
with and without KLF2 mutation, with NOTCH2, TRAF3 and TNFAIP3 mutations being significantly 278 
associated with KLF2 mutations (Figure 4C, P=0.007, P=0.012 and P=0.015 respectively). In line with 279 
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the recent studies, 13,14,16  NOTCH2 mutations were characterised by frameshift insertion/deletion, 280 
and nonsense mutations, which were clustered at the C-terminus and predicted to eliminate the C-281 
terminal PEST, a domain critical for NOTCH2 proteasomal degradation (Figure 3).   TRAF3 and 282 
TNFAIP3 mutations were featured by frameshift insertions/deletion and nonsense mutations, while 283 
CARD11 mutations were typically activating changes reported elsewhere (Figure 3).32,33 284 
 285 
Third, most SMZL without KLF2 mutation showed heterogeneous usage of IGHV in their rearranged 286 
IGH genes, and the majority of these rearranged IGHV harboured high loads of somatic mutations.  287 
Interestingly, MYD88 mutations were exclusively seen in cases without KLF2 mutation (Figure 4A&C, 288 
P=0.021).  MYD88 mutations were typically those of activating changes, while TP53 mutations were 289 
characteristic inactivating changes reported elsewhere.      290 
 291 
Mutation in CD79A and CD79B (both seen in a single case), BCL10 [2 cases, both mutations predicted 292 
a C-terminal truncated BCL10 with a potential gain of function34], and  IKBKB (1 case) was found to 293 
be low in SMZL.  Interestingly, these mutations were mutually exclusive from CARD11 mutations.   294 
Correlation among genetic abnormalities and clinicopathological parameters 295 
 296 
Follow-up data were available for 60 cases of SMZL, ranging from 12 to 288 months (median = 55 297 
months).  Kaplan-Meier univariate analysis of the genetic and clinical variables showed that only 298 
TP53 mutation was significantly associated with poor 5-year overall survival (P =0.002) (Table S7).  299 
However, the number of cases and death events were not sufficient for reliable multivariate analysis.   300 
 301 
DISCUSSION  302 
 303 
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By WES and validation of the mutations identified, we have made several novel and significant 304 
discoveries in the present study.  First, KLF2 is frequently mutated in SMZL (42%), but not or rarely in 305 
other lymphomas;  second, KLF2 mutations are characterised by frameshift insertion/deletion, 306 
nonsense mutations, and a cluster of missense mutations in the ZF1 domain, which impair KLF2 307 
function;  third, there are distinct genetic changes according to KLF2 mutation status.   IGHV1-2 308 
rearrangement and 7q deletion are essentially seen in SMZL with KLF2 mutation, while MYD88 and 309 
TP53 mutations are nearly exclusively seen in those without KLF2 mutation.  Mutations in NOTCH2, 310 
TRAF3, TNFAIP3 and CARD11 genes were found in SMZL both with and without KLF2 mutation.   311 
These distinct mutation patterns indicate overlapping molecular mechanisms between SMZL with 312 
and without KLF2 mutation, and also suggest the presence of different oncogenic cooperation 313 
between the two subgroups.  314 
 315 
KLF2 mutation and its distinctively associated genetic changes  316 
            317 
Among the diverse spectrum of mutations identified in SMZL, KLF2 mutation (42%) is the most 318 
frequent genetic change, much higher than the recently identified NOTCH2 mutation (6.5-25%).13-16  319 
The nature of KLF2 mutations and our in vitro functional studies of KLF2 mutants indicate that these 320 
mutations inactivate KLF2 function.   321 
 322 
A pathogenic role of KLF2 inactivating mutations in SMZL is strongly supported by recent findings, 323 
particularly those by studies of Klf2 knockout mice.  Remarkably, B-cell specific Klf2-deficient mice 324 
show a dramatic increase of marginal zone B-cells.27-29  Klf2 deficiency appears to promote follicular 325 
B-cells to gain a marginal zone like phenotype and migrate to the splenic marginal zone, but have 326 
little impact on their proliferation.27-29  The molecular mechanism underlying the altered B-cell 327 
homeostasis and trafficking in Klf2-deficient mice is unclear although Klf2 most likely exerts such 328 
effects through transcriptional regulation of its target genes. 329 
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 330 
KLF2 is a member of the KLF family of transcription factors, and has been recently shown to be a 331 
negative regulator of inflammation and NF-B activities.35-38  KLF2 appears to regulate NF-B 332 
activities by modulating recruitment of critical NF-B coactivators.38  Using an in vitro reporter assay, 333 
we showed that wild type KLF2 was a potent inhibitor of NF-B activation by several signalling 334 
pathways including BCR (CARD11 mutant), TLR (MYD88 mutant), TNFR (TNFα) and BAFFR (BAFF).  In 335 
contrast, KLF2 mutants had a total or major loss in suppression of NF-B activation triggered by 336 
these signals.  Given the importance of TLR, canonical and non-canonical NF-B pathways in the 337 
development of marginal zone B-cells,39,40 KLF2 inactivation by mutation may exert its oncogenic 338 
activities at least in part by deregulation of NF-B activities triggered by these signals, leading to 339 
altered gene expression favouring B-cells homing to the marginal zone.   However, KLF2 inactivation 340 
alone is insufficient for malignant transformation, and requires cooperating genetic and cellular 341 
events in SMZL development.      342 
 343 
The majority of SMZL with KLF2 mutation have both 7q deletion and IGHV1-2 rearrangement.   The 344 
genes targeted by 7q deletion are unclear.11,12  IGHV1-2 usage is over-represented in SMZL, 345 
accounting for 30% of cases.  Although the epitope recognised by IGHV1-2 expressing BCR and its 346 
potential impact on clinicopathological presentation are unknown, the features of IGHV1-2 347 
rearrangements, including minimal somatic mutations and longer CDR3 sequence with common 348 
motifs, suggest a possible selection of T-cell independent marginal zone B-cells by superantigens,7 349 
thus a role of antigenic drive in the lymphomagenesis (Figure 5).  Such active BCR signalling may 350 
cooperate with KLF2 inactivation in SMZL development.   Apart from IGHV1-2 BCR stereotype, there 351 
are further genetic changes that potentially cooperate with KLF2 inactivation although these genetic 352 
changes occur in SMZL both with and without KLF2 mutation.  353 
 354 
Genetic changes common to SMZL both with and without KLF2 mutation  355 
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 356 
NOTCH2, TRAF3, CARD11 and TNFAIP3 mutations were found in SMZL both with and without KLF2 357 
mutation.  NOTCH2, TRAF3 and CARD11 mutations are most likely to enhance the NOTCH2, non-358 
canonical NF-B and BCR signalling respectively,13,14,16,41,42  while TNFAIP3 mutation may augment 359 
several molecular pathways including TNFR, TLR/IL1-R and BCR signalling.43  All these innate signals 360 
are critical for the development of marginal zone B-cells although their precise role remains to be 361 
dissected.  NOTCH2 signalling is critical for generation of marginal zone B-cells and their retention in 362 
the splenic marginal zone.44-47  Active NOTCH2 signalling alone appears to have little impact on cell 363 
proliferation and survival, but sensitises B-cells to stimulation of surface TLR and CD40.46,47  Non-364 
canonical NF-B signalling, typically triggered by stimulation of surface BAFFR and CD40, is also 365 
pivotal in development of marginal zone B-cells and formation of the splenic marginal zone.48  366 
Chronic active BCR signalling promotes cellular proliferation and survival, and TLR signalling may 367 
contribute to both the development and survival of marginal zone B-cells.40  Marginal zone B cells 368 
express NOTCH2, BAFFR, CD40, and  high levels of TLRs, while the splenic innate lymphoid cells (ILCs) 369 
express surface DLL1 (Notch ligand Delta-like 1),  BAFF, CD40L and provide contact-dependent help 370 
to marginal zone B-cells by stimulation of the respective receptors in a cooperative manner.39,40,49 371 
Thus, NOTCH2, TRAF3, CARD11 and TNFAIP3 mutation may cooperate with the aforementioned 372 
surface receptor stimulation and cause constitutive activation of the corresponding signalling 373 
pathway.   374 
 375 
The respective signalling enhanced by NOTCH2, TRAF3, TNFAIP3 and CARD11 mutation likely 376 
complements the molecular mechanism deregulated by KLF2 mutation, IGHV1-2 expressing BCR and 377 
genes targeted by 7q deletion, thus cooperating in SMZL development (Figure 5).   However, the 378 
genetic events that cooperate with these mutations in SMZL without KLF2 mutation are unclear.      379 
 380 
Genetic changes preferentially associated with SMZL without KLF2 mutation  381 
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 382 
There are also several interesting features in SMZL without KLF2 mutation, including infrequent 7q 383 
deletion and IGHV1-2 rearrangement, and nearly exclusive association with MYD88 and TP53 384 
mutations (Figure 5).  Among SMZL without KLF2 mutation, there is a heterogeneous usage of IGHV 385 
and the majority of these rearranged IGHV genes show high levels of somatic mutations, suggesting 386 
origin from T-cell dependent marginal zone B-cells.50   387 
 388 
The MYD88 mutations seen in SMZL are typically those of gain-of-function change, capable of 389 
spontaneously assembling a signalling complex to activate NF-κB, STAT3 and AP1 transcription 390 
factors.51  MYD88 activation by mutation may lead to biological consequences similar to that by TLR 391 
activation implicated by KLF2 and/or TNFAIP3 inactivation.   392 
 393 
The TP53 mutations seen in SMZL were typically those reported elsewhere, and these mutations 394 
likely inactivate TP53 function.  TP53 mutation in SMZL, like in other lymphomas, is likely to be a 395 
secondary genetic event.   In line with this, TP53 inactivation is associated with progression and poor 396 
prognosis in  SMZL.12,52,53 397 
 398 
In summary, there are common and distinct genetic changes between SMZL with and without KLF2 399 
mutation and these different genetic changes most likely deregulate several signalling pathways 400 
important for the generation of marginal zone B-cells, their migration and retention in the splenic 401 
marginal zone.   Each of these genetic changes may have a predominant impact on a particular 402 
biological process and contribute to the lymphoma development through oncogenic cooperation 403 
with other concurrent changes (Figure 5).  It is pertinent to tentatively speculate that 1) KLF2 404 
inactivation may deregulate gene expression through the modulation of NF-B activities and other 405 
unknown mechanisms, thereby promoting B-cells homing to the splenic marginal zone; 2) NOTCH2 406 
activation, TRAF3 and TNFAIP3 inactivation and MYD88 activation by mutations may contribute to 407 
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the generation of marginal zone B-cells and their retention in the splenic marginal zone by 408 
augmenting the NOTCH2, non-canonical NF-B pathway and TLR signalling respectively;  3) IGHV1-2 409 
rearrangement and CARD11 activation by mutations may lead to chronic active BCR signalling, 410 
consequently enhancing cell proliferation and survival.   A simultaneous deregulation of the above 411 
signalling pathways in SMZL with KLF2 mutation may generate complementary properties in 412 
oncogenic cooperation, leading to lymphoma development.    413 
 414 
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FIGURE LEGENDS: 573 
Figure 1:  Nature and incidence of KLF2 mutations in SMZL and other B-cell lymphomas.      574 
 575 
A)  Nature and distribution of KLF2 mutations in lymphoma.  The majority of KLF2 mutations seen in 576 
SMZL are frameshift deletion / insertion or nonsense mutations.   Missense mutations are largely 577 
clustered in ZF1 (zinc finger), particularly at conserved amino acid residues.  Mutations were 578 
confirmed by two independent PCR and sequencing experiments.  Where possible the somatic 579 
nature of the mutation identified was confirmed by PCR and sequencing analysis of the paired non-580 
tumour DNA and indicated by red symbols.  Mutations identical to those confirmed to be somatic 581 
are highlighted in blue. Concurrent mutations seen in the same cases are indicated by their case 582 
number.      583 
 584 
B) Frequencies of KLF2 mutations in SMZL and various other B-cell lymphomas.  585 
 586 
ZF: zinc finger; NLS: putative nuclear localisation signal.   587 
 588 
Figure 2:  Functional characterisation of KLF2 mutations.  589 
 590 
A) The representative KLF2 mutants investigated by in vitro reporter assays, which include three 591 
truncation, two recurrent missense and one in-frame deletion mutants.  The missense change and 592 
in-frame deletion affect the conserved amino acid residues.   593 
 594 
B) NF-B reporter assay shows that wild type KLF2 is a potent inhibitor of NF-B activation by TNFα, 595 
BAFF, MYD88 and CARD11 mutants in both HEK293T and OCI-LY19 B-lymphoma cells.  With the 596 
exception of KLF2-A291V mutant, all other 5 mutants including KLF2-C274Y and KLF2-TY mutants 597 
showed a total or major loss in NF-κB suppression.  Interestingly, both the cases with KLF2-A291V 598 
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had a second mutation, one with P70S in the activation domain, the other with C274S.  The data is 599 
from at least three independent experiments and presented as a mean ± standard deviation, and the 600 
difference between KLF2 and its mutants is analysed by the Student t-test.  As indicated by an 601 
arrowhead, the KLF2-AD-ZF1 mutant consistently shows an additional band, ~7 kDa larger than the 602 
expected size (32 kDa).  We have performed a series of experiments to confirm the correct sequence 603 
and also rule out any cross-contamination of an additional clone.  The band shift is most likely 604 
caused by post-translational modifications, but its nature remains to be established. * P < 0.05, ** P 605 
< 0.01, *** P < 0.001. 606 
 607 
 608 
Figure 3:  Nature and distribution of mutations in NOTCH2, TNFAIP3, TRAF3, CARD11, MYD88 and 609 
TP53 in SMZL.    NOTCH2 mutations are characterised by frameshift insertion/deletion, and nonsense 610 
mutations that are clustered at the C-terminus and predicted to eliminate the C-terminal PEST, a 611 
domain critical for NOTCH2 proteasomal degradation.   TNFAIP3 and TRAF3 mutations are featured 612 
by frameshift insertion/deletion and nonsense mutations, which inactivate their protein functions.  613 
CARD11 and MYD88 mutations are typically those of activating changes reported elsewhere.  TP53 614 
mutations are also characteristic inactivating changes extensively reported in the literature.   The 615 
mutations identified by Fluidigm PCR and MiSeq sequencing are confirmed either by an independent 616 
Fluidigm PCR and MiSeq sequencing or Sanger sequencing.  Where possible, the somatic nature of 617 
mutation was determined: those confirmed by PCR and sequencing of the paired non-tumour DNA 618 
are shown by red symbols, while those identified in a search of the COSMIC somatic mutation 619 
database are shown by blue symbols.  Concurrent mutations seen in the same cases are indicated by 620 
their case number. 621 
 622 
LNR: LIN-12/NOTCH repeats; HD: heterodimerisation; TM: transmembrane; RAM: regulation of 623 
amino acid metabolism; TAD: transactivation domain; PEST: Proline, glutamic acid, serine and 624 
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threonine rich domain; ZF: zinc finger; CARD: caspase recruitment domain; PDZ: (PSD95, DLG and 625 
ZO1 homology) domain; SH3: Src homology motif; GUK: guanylate kinase domain  626 
 627 
Figure 4:  Correlation of KLF2 mutation with other genetic changes in SMZL.   628 
A)  Heatmap shows KLF2 mutation and other genetic changes in 101 cases of SMZL.   Rows 629 
correspond to genetic change, while columns indicate individual cases.  Positive genetic changes are 630 
shown in green. Genes included in the BCR pathway mutations are CARD11, BCL10, CD79A and 631 
CD79B.   632 
B) Frequencies of KLF2 mutation and other genetic changes in SMZL;  633 
C) Correlation among KLF2 mutation and other genetic changes in SMZL.    KLF2 mutation is 634 
significantly and positively associated with 7q deletion, IGHV1-2 usage, NOTCH2, TRAF3 and TNFAIP3 635 
mutations, but negatively correlated with MYD88 mutation.  BCR:  B-cell receptor; Mut: mutation; 636 
Del: deletion. 637 
 638 
Figure 5:   A summary of the proposed molecular mechanism of SMZL.   639 
The majority of SMZL with KLF2 mutation have the rearranged IGHV1-2 that carries minimal levels of 640 
somatic mutations, suggesting derivation of these lymphoma cells from T-cell independent marginal 641 
zone B-cells.  The biased usage of IGHV1-2 indicates possible antigenic drive by superantigen, hence 642 
chronic BCR signalling.   KLF2 inactivation by mutation may facilitate marginal zone B-cell 643 
differentiation and their homing to the splenic marginal zone.   7q deletion is predominately seen in 644 
cases with KLF2 mutation and its role in the lymphoma pathogenesis is unknown.   645 
CARD11, NOTCH2, TRAF3 and TNFAIP3 mutations are found in cases with and without KLF2 mutation.  646 
Mutations in CARD11 and others (CD79A/B, BCL10) may lead to active BCR signalling, thereby 647 
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promoting cell proliferation and survival.   Activation of NOTCH2, BAFFR/CD40 and TLR signalling by 648 
NOTCH2, TRAF3 and TNFAIP3 mutation may primarily contribute to marginal zone B-cell generation 649 
and their retention in the splenic marginal zone.   650 
The majority of SMZL without KLF2 mutation have heterogeneous usage of IGHV that carries high 651 
loads of somatic mutation, suggesting origination of these lymphoma cells from T-cell dependent 652 
marginal zone B-cells.  MYD88 and TP53 mutations are nearly exclusively seen in cases without KLF2 653 
mutation.  MYD88 mutation most likely causes constitutive TLR signalling, while TP53 mutation 654 
inactivates its tumour suppressor function and may promote disease progression and high-grade 655 
transformation.          656 
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Figure 3: Nature and distribution of mutations in NOTCH2, TNFAIP3, TRAF3, CARD11, MYD88 and TP53 in SMZL.     
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Figure 4:  Correlation of KLF2 mutation with other genetic changes in SMZL.   
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Figure 5:   A summary of the proposed molecular mechanism of SMZL.   
